Actavis Inc (ACT) 295.41 $ACT
Big Pharma Comes Under Attack From a New Hedge Fund Strategy
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 26, 10:04AM CDT
Source: Teva Pharmaceutical, Facebook. Forget retail short-sellers and angry message board posters, Big Pharma has a much bigger concern on the horizon: hedge funds. I know what you're probably thinking, "Haven't various hedge funds already been...
ACT: 295.41 (-2.95), SHPG: 255.11 (-0.26), PFE: 35.27 (-0.09), JAZZ: 189.42 (+0.33), TEVA: 64.41 (+1.16)
3 Best Stocks for Investing in Generic Drugs
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 25, 11:02AM CDT
Source: FoolEditorial on Flickr. Americans spent more on prescription drugs last year than ever before -- nearly $374 billion, according to IMS Health . That figure reflected a 13.1% jump over 2013 spending. Health insurers and government...
MNK: 122.01 (-2.84), ACT: 295.41 (-2.95), AKRX: 55.24 (-0.68)
Orexigen: Contrave Sales Pop, Equity Response Muted
Spencer Osborne - at Seeking Alpha - Fri Apr 24, 6:39PM CDT
OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)
The Parade of Weak Earnings Reports Continues - Earnings Preview
Sheraz Mian - ZACKS - Fri Apr 24, 2:39PM CDT
The Parade of Weak Earnings Reports Continues - Earnings Preview
ACT: 295.41 (-2.95), F: 15.77 (+0.01), ETN: 68.58 (-0.52), PFE: 35.27 (-0.09), IP: 53.67 (+0.79), COP: 67.51 (-0.75), XOM: 86.97 (-0.57), BAC: 15.64 (-0.05), UPS: 98.10 (-0.12), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), CVS: 101.58 (+0.70), CVX: 109.87 (-0.10), AAPL: 130.28 (+0.61), VIAB: 70.74 (+0.04), MA: 90.72 (-0.16)
Actavis Announces Topline Phase 3 Clinical Trial Results for Single-Dose DALVANCE® (dalbavancin) in the Treatment of ABSSSI
PR Newswire - Fri Apr 24, 8:25AM CDT
Actavis plc (NYSE: ACT) today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA).
ACT: 295.41 (-2.95)
Orexigen Investors Can Get Litigation Insight From Vivus
Spencer Osborne - at Seeking Alpha - Fri Apr 24, 7:29AM CDT
OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), VVUS: 2.46 (-0.04)
Orexigen's Obesity Drug Contrave Faces Generic Threat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 5:37PM CDT
Orexigen (OREX) and partner Takeda received a Paragraph IV certification from Actavis, which is looking to get its generic version of Contrave approved in the U.S.
OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), ARNA: 4.49 (+0.05)
Orexigen - Contrave Sales Outpace Competition, But Are Still Not Enough
Spencer Osborne - at Seeking Alpha - Thu Apr 23, 7:32AM CDT
OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)
Actavis Launches AVYCAZ(TM) (Ceftazidime-Avibactam) Anti-Infective In U.S.
PR Newswire - Thu Apr 23, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced AVYCAZ(TM) (ceftazidime-avibactam) is now available for ordering by hospitals across the United States. AVYCAZ is indicated for the treatment of adult patients with complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae and Pseudomonas aeruginosa. As only limited clinical safety and efficacy data for AVYCAZ are currently available, AVYCAZ should be reserved for use in patients who have limited or no alternative treatment options.
ACT: 295.41 (-2.95)
15 'Sustainable' Companies Not Named Apple to Buy Right Now
at The Street - Wed Apr 22, 3:45PM CDT
American companies topped the list of global corporate sustainability leaders in 2015, but are they good investments? We take a look on earth day 2015.
KO: 40.89 (-0.06), BIIB: 401.71 (-28.57), ACT: 295.41 (-2.95), GE: 26.80 (-0.05), A: 42.49 (-0.13), INTC: 32.08 (-0.27), ADBE: 76.54 (+0.02), JNJ: 101.08 (+0.62), SIAL: 139.00 (+0.03), CPB: 45.81 (-0.26), GIS: 56.38 (+0.09), CSCO: 28.82 (+0.15), CL: 69.17 (-0.05), ECL: 115.59 (-0.26), JCI: 52.48 (-0.42)
Teva Proposes to Buy Mylan, Sends Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:11PM CDT
Teva (TEVA) made an offer to acquire Mylan (MYL) for $82 per share in a deal that would create a powerhouse of generics with revenues of more than $30 billion.
ACT: 295.41 (-2.95), PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
Orexigen Faces Generic Challenge For Anti-Obesity Drug
Spencer Osborne - at Seeking Alpha - Wed Apr 22, 11:24AM CDT
OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), VVUS: 2.46 (-0.04)
Teva offers to buy Mylan in $40.1B cash-and-stock deal
By LINDA A. JOHNSON - AP - Tue Apr 21, 4:30PM CDT
TRENTON, N.J. (AP) — Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
AGN: 240.22 (+2.88), ACT: 295.41 (-2.95), ASPX: 100.88 (-0.01), TEVA: 64.41 (+1.16)
Actavis' Botox Upper Limb Spasticity Label Expanded by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:08PM CDT
Actavis' (ACT) Botox has been granted further FDA approval; adds upper limb spasticity to its label.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), ACT: 295.41 (-2.95), AVEO: 1.92 (-0.08)
Pharma Spends Big On M&A In Q1 As Teva Pulls Trigger On Mylan
EP Vantage - Seeking Alpha - Tue Apr 21, 2:25PM CDT
The pharma and biotech buying spree showed no sign of abating in the opening months of 2015, with $69bn committed across 62 deals in the first quarter, EvaluatePharma data show. And with Teva (NYSE: TEVA ) confirming its interest in ...
AGN: 240.22 (+2.88), VRX: 210.42 (+1.03), ACT: 295.41 (-2.95), PFE: 35.27 (-0.09), MYL: 76.06 (+2.37), ABBV: 66.07 (+1.82), TEVA: 64.41 (+1.16)
Actavis reports planned departure of chief communications officer Charles M Mayr
M2 - Tue Apr 21, 7:31AM CDT
Pharmaceutical company Actavis plc (NYSE:ACT) revealed on Monday the retirement of its chief communications officer, Charles M Mayr due to health reasons.
ACT: 295.41 (-2.95)
Actavis Announces Retirement of Charles M. Mayr
PR Newswire - Mon Apr 20, 3:15PM CDT
Actavis plc (NYSE: ACT) today announced that Charles M. Mayr, Chief Communications Officer, will retire from Actavis on May 15, 2015 due to health reasons. In conjunction with Mayr's retirement, Alex Kelly, Chief Integration Officer, will assume the role of Chief Communications Officer, effective immediately. Prior to joining Actavis in 2014, Kelly served as Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations at Forest Laboratories.
ACT: 295.41 (-2.95)
Actavis Announces FDA Approval of Expanded Label for BOTOX® (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults
PR Newswire - Mon Apr 20, 7:00AM CDT
Actavis plc (NYSE: ACT), which recently completed the acquisition of Allergan, today announced that the United States Food and Drug Administration (FDA) has approved an expansion of the BOTOX® (onabotulinumtoxinA) label for the treatment of adults with upper limb spasticity. The expanded label now includes the addition of two thumb muscles: flexor pollicis longus, a muscle in the forearm that flexes the thumb; and adductor pollicis, a muscle in the hand that functions to adduct the thumb; increasing the maximum dose from 360 to 400 units for the treatment of upper limb spasticity. The FDA also approved an increase to the maximum BOTOX® cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.
AGN: 240.22 (+2.88), ACT: 295.41 (-2.95)
Global Worries Sink U.S. Stocks; Apple Breaches Support Level
at Investor's Business Daily - Fri Apr 17, 3:37PM CDT
Stocks closed sharply lower, though off their worst levels of the day, as concerns about Greece and new Chinese regulations weighed throughout the session. The Nasdaq and Dow Jones industrial average each sank 1.5%, while the S&P 500 gave up 1.1%....
ACT: 295.41 (-2.95), AKRX: 55.24 (-0.68), MYL: 76.06 (+2.37), FLTX: 46.62 (-1.73), ATHM: 53.31 (+0.92), LCI: 67.40 (unch), PNK: 36.73 (+0.45), NOW: 76.09 (-0.79), MAT: 30.20 (+1.28), TEVA: 64.41 (+1.16), AAPL: 130.28 (+0.61), UVE: 25.22 (-0.20)
Big Pharma Comes Under Attack From a New Hedge Fund Strategy
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 26, 10:04AM CDT
Source: Teva Pharmaceutical, Facebook. Forget retail short-sellers and angry message board posters, Big Pharma has a much bigger concern on the horizon: hedge funds. I know what you're probably thinking, "Haven't various hedge funds already been...
ACT: 295.41 (-2.95), SHPG: 255.11 (-0.26), PFE: 35.27 (-0.09), JAZZ: 189.42 (+0.33), TEVA: 64.41 (+1.16)
3 Best Stocks for Investing in Generic Drugs
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 25, 11:02AM CDT
Source: FoolEditorial on Flickr. Americans spent more on prescription drugs last year than ever before -- nearly $374 billion, according to IMS Health . That figure reflected a 13.1% jump over 2013 spending. Health insurers and government...
MNK: 122.01 (-2.84), ACT: 295.41 (-2.95), AKRX: 55.24 (-0.68)
Orexigen: Contrave Sales Pop, Equity Response Muted
Spencer Osborne - at Seeking Alpha - Fri Apr 24, 6:39PM CDT
OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)
The Parade of Weak Earnings Reports Continues - Earnings Preview
Sheraz Mian - ZACKS - Fri Apr 24, 2:39PM CDT
The Parade of Weak Earnings Reports Continues - Earnings Preview
ACT: 295.41 (-2.95), F: 15.77 (+0.01), ETN: 68.58 (-0.52), PFE: 35.27 (-0.09), IP: 53.67 (+0.79), COP: 67.51 (-0.75), XOM: 86.97 (-0.57), BAC: 15.64 (-0.05), UPS: 98.10 (-0.12), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), CVS: 101.58 (+0.70), CVX: 109.87 (-0.10), AAPL: 130.28 (+0.61), VIAB: 70.74 (+0.04), MA: 90.72 (-0.16)
Actavis Announces Topline Phase 3 Clinical Trial Results for Single-Dose DALVANCE® (dalbavancin) in the Treatment of ABSSSI
PR Newswire - Fri Apr 24, 8:25AM CDT
Actavis plc (NYSE: ACT) today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA).
ACT: 295.41 (-2.95)
Orexigen Investors Can Get Litigation Insight From Vivus
Spencer Osborne - at Seeking Alpha - Fri Apr 24, 7:29AM CDT
OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), VVUS: 2.46 (-0.04)
Orexigen's Obesity Drug Contrave Faces Generic Threat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 5:37PM CDT
Orexigen (OREX) and partner Takeda received a Paragraph IV certification from Actavis, which is looking to get its generic version of Contrave approved in the U.S.
OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), ARNA: 4.49 (+0.05)
Orexigen - Contrave Sales Outpace Competition, But Are Still Not Enough
Spencer Osborne - at Seeking Alpha - Thu Apr 23, 7:32AM CDT
OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)
Actavis Launches AVYCAZ(TM) (Ceftazidime-Avibactam) Anti-Infective In U.S.
PR Newswire - Thu Apr 23, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced AVYCAZ(TM) (ceftazidime-avibactam) is now available for ordering by hospitals across the United States. AVYCAZ is indicated for the treatment of adult patients with complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae and Pseudomonas aeruginosa. As only limited clinical safety and efficacy data for AVYCAZ are currently available, AVYCAZ should be reserved for use in patients who have limited or no alternative treatment options.
ACT: 295.41 (-2.95)
15 'Sustainable' Companies Not Named Apple to Buy Right Now
at The Street - Wed Apr 22, 3:45PM CDT
American companies topped the list of global corporate sustainability leaders in 2015, but are they good investments? We take a look on earth day 2015.
KO: 40.89 (-0.06), BIIB: 401.71 (-28.57), ACT: 295.41 (-2.95), GE: 26.80 (-0.05), A: 42.49 (-0.13), INTC: 32.08 (-0.27), ADBE: 76.54 (+0.02), JNJ: 101.08 (+0.62), SIAL: 139.00 (+0.03), CPB: 45.81 (-0.26), GIS: 56.38 (+0.09), CSCO: 28.82 (+0.15), CL: 69.17 (-0.05), ECL: 115.59 (-0.26), JCI: 52.48 (-0.42)
Teva Proposes to Buy Mylan, Sends Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:11PM CDT
Teva (TEVA) made an offer to acquire Mylan (MYL) for $82 per share in a deal that would create a powerhouse of generics with revenues of more than $30 billion.
ACT: 295.41 (-2.95), PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
Orexigen Faces Generic Challenge For Anti-Obesity Drug
Spencer Osborne - at Seeking Alpha - Wed Apr 22, 11:24AM CDT
OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), VVUS: 2.46 (-0.04)
Teva offers to buy Mylan in $40.1B cash-and-stock deal
By LINDA A. JOHNSON - AP - Tue Apr 21, 4:30PM CDT
TRENTON, N.J. (AP) — Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
AGN: 240.22 (+2.88), ACT: 295.41 (-2.95), ASPX: 100.88 (-0.01), TEVA: 64.41 (+1.16)
Actavis' Botox Upper Limb Spasticity Label Expanded by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:08PM CDT
Actavis' (ACT) Botox has been granted further FDA approval; adds upper limb spasticity to its label.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), ACT: 295.41 (-2.95), AVEO: 1.92 (-0.08)
Pharma Spends Big On M&A In Q1 As Teva Pulls Trigger On Mylan
EP Vantage - Seeking Alpha - Tue Apr 21, 2:25PM CDT
The pharma and biotech buying spree showed no sign of abating in the opening months of 2015, with $69bn committed across 62 deals in the first quarter, EvaluatePharma data show. And with Teva (NYSE: TEVA ) confirming its interest in ...
AGN: 240.22 (+2.88), VRX: 210.42 (+1.03), ACT: 295.41 (-2.95), PFE: 35.27 (-0.09), MYL: 76.06 (+2.37), ABBV: 66.07 (+1.82), TEVA: 64.41 (+1.16)
Actavis reports planned departure of chief communications officer Charles M Mayr
M2 - Tue Apr 21, 7:31AM CDT
Pharmaceutical company Actavis plc (NYSE:ACT) revealed on Monday the retirement of its chief communications officer, Charles M Mayr due to health reasons.
ACT: 295.41 (-2.95)
Actavis Announces Retirement of Charles M. Mayr
PR Newswire - Mon Apr 20, 3:15PM CDT
Actavis plc (NYSE: ACT) today announced that Charles M. Mayr, Chief Communications Officer, will retire from Actavis on May 15, 2015 due to health reasons. In conjunction with Mayr's retirement, Alex Kelly, Chief Integration Officer, will assume the role of Chief Communications Officer, effective immediately. Prior to joining Actavis in 2014, Kelly served as Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations at Forest Laboratories.
ACT: 295.41 (-2.95)
Actavis Announces FDA Approval of Expanded Label for BOTOX® (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults
PR Newswire - Mon Apr 20, 7:00AM CDT
Actavis plc (NYSE: ACT), which recently completed the acquisition of Allergan, today announced that the United States Food and Drug Administration (FDA) has approved an expansion of the BOTOX® (onabotulinumtoxinA) label for the treatment of adults with upper limb spasticity. The expanded label now includes the addition of two thumb muscles: flexor pollicis longus, a muscle in the forearm that flexes the thumb; and adductor pollicis, a muscle in the hand that functions to adduct the thumb; increasing the maximum dose from 360 to 400 units for the treatment of upper limb spasticity. The FDA also approved an increase to the maximum BOTOX® cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.
AGN: 240.22 (+2.88), ACT: 295.41 (-2.95)
Global Worries Sink U.S. Stocks; Apple Breaches Support Level
at Investor's Business Daily - Fri Apr 17, 3:37PM CDT
Stocks closed sharply lower, though off their worst levels of the day, as concerns about Greece and new Chinese regulations weighed throughout the session. The Nasdaq and Dow Jones industrial average each sank 1.5%, while the S&P 500 gave up 1.1%....
ACT: 295.41 (-2.95), AKRX: 55.24 (-0.68), MYL: 76.06 (+2.37), FLTX: 46.62 (-1.73), ATHM: 53.31 (+0.92), LCI: 67.40 (unch), PNK: 36.73 (+0.45), NOW: 76.09 (-0.79), MAT: 30.20 (+1.28), TEVA: 64.41 (+1.16), AAPL: 130.28 (+0.61), UVE: 25.22 (-0.20)
